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Abstract
Background: Japanese encephalitis virus (JEV) is a neurotropic flavivirus causing mortality and morbidity in humans.
Severe Japanese encephalitis cases display strong inflammatory responses in the central nervous system and an
accumulation of viral particles in specific brain regions. Microglia cells are the unique brain-resident immune cell
population with potent migratory functions and have been proposed to act as a viral reservoir for JEV. Animal models
suggest that the targeting of microglia by JEV is partially responsible for inflammatory reactions in the brain.
Nevertheless, the interactions between human microglia and JEV are poorly documented.
Methods: Using human primary microglia and a new model of human blood monocyte-derived microglia, the present
study explores the interaction between human microglia and JEV as well as the role of these cells in viral transmission
to susceptible cells. To achieve this work, vaccine-containing inactivated JEV and two live JEV strains were applied on
human microglia.
Results: Live JEV was non-cytopathogenic to human microglia but increased levels of CCL2, CXCL9 and CXCL10 in
such cultures. Furthermore, human microglia up-regulated the expression of the fraktalkine receptor CX3CR1 upon
exposure to both JEV vaccine and live JEV. Although JEV vaccine enhanced MHC class II on all microglia, live JEV
enhanced MHC class II mainly on CX3CR1
+ microglia cells. Importantly, human microglia supported JEV replication, but
infectivity was only transmitted to neighbouring cells in a contact-dependent manner.
Conclusion: Our findings suggest that human microglia may be a source of neuronal infection and sustain JEV brain
pathogenesis.
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Background
Japanese encephalitis (JE) is an acute inflammatory dis-
ease of the central nervous system (CNS) caused by the
neurotropic flavivirus JE virus (JEV). JEV is a single
stranded positive sense RNA virus endemic in the Asia-
Pacific region, including China, India and northern
Australia [1]. JEV is transmitted by mosquito vectors via
a zoonotic cycle involving pigs as amplifying and water
birds as reservoir host, the latter do not typically develop
illness upon JEV infection [2]. Humans are considered
to be dead-end hosts, since low viremia does not allow
further virus transmission [1].
Markedly, competent vectors for JEV have been re-
cently identified in Germany [3] and the ability of JEV to
persist and transmit between pigs in absence of mosqui-
tos [4] are increasing risks of virus spread and persist-
ence in regions with more moderate climate and
becoming a worldwide public health concern. While less
than 1% of JEV infected patients develop JE, it is esti-
mated ~70,000 annual human symptomatic JE cases to
happen, where 25-30% are fatal and 50% of surviving pa-
tients develop permanent neurological damage [5, 6]. In
regions at risk, vaccination programs are available [5].
By an unknown mechanism, JEV invades the CNS in-
fecting and killing neurons with a specific tropism for
developing neurons [7, 8]. In brain autopsies of fatal JE
patients, JEV–infected neurons are localized in the thal-
amus, in the brainstem, as well as in the hippocampus,
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which are areas of neuronal turn-over, even in adults [9].
Accumulating evidences highlight the prominent role of
the cells of the macrophage lineage in JEV pathogenesis.
In fact, human blood monocytes survive from productive
infection by JEV and can maintain infectious virus for 5
days [10]. Human blood monocyte-derived dendritic
cells (MoDC) and monocyte-derived macrophages
(MDM) support virus replication in vitro [11, 12].
Microglial cells are the unique resident immune cells
of the nervous system, which populate the brain during
early development, but can also derive from blood
monocytes after birth under specific conditions [13].
Microglia are involved in immune surveillance of the
CNS and have potent migratory functions driven by che-
mokine ligands/receptors interactions, as well as phago-
cytic and antigen presentation abilities [14, 15]. Mouse
microglia are activated and produce numbers of pro-
inflammatory factors upon JEV infection in vivo and in
vitro [16]. Moreover, mouse microglia are productively
infected by JEV in vitro and are proposed to play a role
in long-lasting infection [17].
Despite differences between humans and most of ani-
mals, rodent models are widely used in the laboratory to
characterize and understand JEV pathogenicity. The
present study explores the interactions between human
microglia and JEV. To achieve this work, vaccine-
containing inactivated JEV and two live JEV strains were
applied in-vitro on human primary microglia and human
monocyte-derived microglia. Our results show that
human microglia were activated upon JEV exposure,
without affecting viability. Indeed, JEV-exposed human
microglia acquired an inflammatory state, characterized
by increased levels of chemokine ligands such as CCL2,
CXCL9 and CXCL10 and increased expression of the
fraktalkine receptor CX3CR1. Furthermore, JEV en-
hanced MHC class II expression. Finally, human micro-
glia supported viral replication but cell-cell contact was
required for viral transmission to other cells. The
present study demonstrates the implication of human
microglia in inflammatory responses and virus propaga-
tion upon exposure to JEV.
Methods
Authorization
Authorization (number A130522) was obtained from the
Federal Office for the Environment (FOEN, Bern,
Switzerland) for collection of human samples and ma-
nipulation of the various cells and viruses. All samples
were analysed anonymously.
Preparation of human microglial cells and cell culture
Human primary microglia cells (BdMG) were isolated
from the cortex of brains derived from an anonymous
donor of the body donation program of the University of
Fribourg according to a newly established protocol from
[18]. Briefly, the brain was excised within 8 h post-
mortem. The 20 mL of minced cortex tissue was
digested at room temperature for 24 h under gentle
shaking in 75 cm2 culture flasks (Corning Incorporated,
Corning, NY), containing 30 mL Roswell Park Memorial
Institute-1640 (RPMI-1640) GlutaMAX™-I medium sup-
plemented with 2x antibiotics/antimycotic and 0.5x
trypsin/EDTA (all from Life Technologies). The resulting
single cells in suspension were further enriched through
filtering through Smarttrainer (100 μm, Miltenyi Biotec
GmbH, Bergisch-Gladbach, Germany) and Ficoll-Paque
density gradient centrifugation (1.077 g/L, Amersham
Pharmacia Biotech AG, Dubendorf, Switzerland). The
cells were then cultured in RPMI-1640 GlutaMAX™-I
medium supplemented with 1x antibiotic/antimycotic
and 5% v/v human serum (HS) (heat inactivated, ob-
tained from Don du sang, Lausanne, Switzerland) at
37 °C and 5% CO2.
Human blood monocyte-derived microglia (M-MG)
were generated from buffy coats of anonymous healthy
donors, alternatively obtained from Don du sang
(Lausanne, Switzerland) and Blutspendedienst (Bern,
Switzerland), as previously described [19]. Briefly, hu-
man peripheral blood mononuclear cells (PBMC) were
isolated from buffy coat after Ficoll-Paque density gradi-
ent centrifugation. PBMC were cultured in 25 cm2 cul-
ture flasks (Corning, Incorporated) in RPMI-1640
GlutaMAX™-I medium supplemented with 1x antibiotic/
antimycotic for at least 2 h allowing adherence of cells.
After adherence, non-adherent cells and contaminants
were washed away. For differentiation toward microglia,
adherent cells, mainly monocytes, were cultured in
complete medium consisting of RPMI-1640 GlutaMAX™-I
medium supplemented with 1x antibiotic/antimycotic and
the following bioactive human recombinant cytokines
(purchased from Miltenyi Biotec GmbH, Bergisch-
Gladbach, Germany) at the indicated concentration:
granulocyte macrophage colony-stimulating factor
(GM-CSF) (10 ng/mL), macrophage colony-stimulating
factor (M-CSF) (10 ng/mL), nerve growth factor
(NGF)-β (10 ng/mL) and CC chemokine ligand 2 (CCL2)
(50 ng/mL) at 37 °C and 5% CO2 for 7–10 days.
Baby Hamster Kidney-21 cells (BHK-21) ([C-13],
ATCC, Wesel, Germany) were cultured in Glasgow’s
Minimum Essential Medium (GMEM) (Life Technologies,
Zug, Switzerland) supplemented with 5% v/v Fetal Bovine
Serum (FBS) (Biowest, Nuaillé, France) and Tryptose
Phosphate Broth solution (Sigma-Aldrich, Saint Louis,
MO) at 37 °C and 5% CO2.
Viruses: source, propagation and titration
JEV vaccine, manufactured by Intercell AG (Vienna,
Austria) and commercialized under the name Ixiaro® by
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Novartis (Basel, Switzerland), was obtained from the
Inselspital Pharmacy (Bern, Switzerland). One dose of
Ixiaro® consists of 6 μg of formalin-inactivated SA14-14-2
isolate protein (Vero cell-derived attenuated JEV isolate)
and aluminium hydroxide adjuvant (0.25 mg Al3+) in
0.5 mL suspension PBS solution [20]. Filtered suspension
of aluminium hydroxide (0.5 mg/mL) (Sigma-Aldrich) in
PBS was used as control.
Nakayama and TC362 isolates (National collection of
pathogenic viruses, NCPV, Salibury, UK) were propa-
gated and titrated in BHK-21. Briefly, 80% confluent
BHK-21 monolayer cell culture was infected with JEV
suspended in RPMI-1640 GlutaMAX™-I medium supple-
mented with 2% FBS. Cells were cultured until cytopath-
ogenic effects appear (approx. 36–48 h). Remaining cells
were disrupted by freezing and cell soup was centrifuged
at 3000 g at 4 °C for 30 min to eliminate cell debris.
Viral titres were determined by end-point titration on
BHK-21 cells. To this end, 10-fold serial dilutions of the
virus stocks were applied on cell cultures for 36–48 h at
37 °C, 5% CO2. Then, intracellular viral particles were
detected with the pan-immune anti-flavivirus antibody
(mouse clone ATCC-HB-112 D1-4G2-4-15 hybridoma,
ATCC, Wesel, Germany) followed by peroxidase enzym-
atic reaction. As control, mock antigen was prepared from
uninfected BHK-21 cells in the same manner as JEV.
Treatment of human microglial cells with JEV and
co-culture with BHK-21 cells
In experiments, human microglia were cultured in
serum-free RPMI-1640 GlutaMAX™-I medium. Addition
of serum abrogated the responsiveness of human
microglia (data not shown). At a concentration of 5x105
cells/mL, human microglia were treated either with JEV
vaccine or live JEV in RPMI-1640 GlutaMAX™-I
medium at 37 °C and 5% CO2. After treatment, cells and
supernatants were separately collected for further
analysis. In some experiments, supernatants were stored
at -80 °C until further experiments.
In some experiments, JEV-treated human microglia:
BHK-21 cells (10: 1) were co-cultured in serum-free
RPMI-1640 GlutaMAX™-I medium for 2 days at 37 °C in
5% CO2. Before addition of BHK-21 cells, JEV-treated
human microglia were intensively washed with fresh
medium and last washing was verified negative for infec-
tious JEV. On one hand, human microglia and BHK-21
cells were cultured in cell-cell contact condition by
addition of BHK-21 cells on top of human microglia. On
another hand, human microglia and BHK-21 cells were
separated using transwell insert (0.4 μm polyester mem-
brane, Corning, Incorporated), allowing the passage of
small material such as viral particles but not cells. In these
conditions, the lower chamber contained human microglia
and the upper chamber contained BHK-21 cells.
Bright field microscopy
Cells in culture were observed with an Eclipse TS1000
light microscope (Nikon AG, Egg, Switzerland) and
photographed using a EOS 600D Camera (Canon SA,
Wallisellen, Switzerland).
Transmission electron microscopy
Cells were successively fixed with 0.05% glutaraldehyde
and 4% paraformaldehyde. Then, cells were embedded in
LR White medium grade acrylic resin (SPI Supplies,
West Chester, PA). Ultrathin sections (0.05 μm thick)
contrasted with negative stain uranyl acetate solution
(Sigma-Aldrich) and analysed using a CM100-Biotwin
transmission electron microscope (Philips SA, Zürich,
Switzerland).
Antibodies and flow cytometry
For phenotyping, fluorescent-labelled anti-human anti-
bodies against the following cell surface markers were
employed and purchased from BD Biosciences (San Jose,
CA) otherwise stated: CCR1-Alexa Fluor 647 (AF647)
(CD191, clone 53504), CCR2-AF647 (CD192, clone
48607), CCR3-R-Phycoerythrin (R-PE) (CD193, clone
5E8), CCR4-Peridin chlorophyll protein (PerCP)-Cy5.5
(CD194, clone 1G1), CCR5- Allophycocyanin (APC)-
Cy7 (CD195, clone 2D7/CCR5), CXCR1-Fluorescein iso-
thiocyanate (FITC) (CD181, clone 5A12), CXCR2-FITC
(CD182, clone 6C6), CXCR3-R-PE-Cy5 (CD183, mouse
clone 1C6/CXCR3), CXCR4-R-PE-Cy5 (CD184, mouse
clone 12G5), CXCR5-AF488 (CD185, clone RF8G2),
CX3CR1-R-PE (clone 2A9-1 from Miltenyi Biotec GmbH,
Bergisch-Gladbach, Germany) and MHC class II-APC
(HLA-DR, clone G46-6). Corresponding fluorescent-
labelled isotype antibody controls were selected according
to manufacturer’s recommendations. In addition, MHC
class I (mouse clone PT85A, IgG2a, VRMD Inc, Pullman,
WA) and goat anti-mouse all IgG fluorescent-labelled
with R-PE (BD Biosciences) were used.
Viral particles were detected intracellularly using
the pan-immune anti-flavivirus antibody (ATCC) as
primary antibody. Secondary antibody was the goat
anti-mouse IgG1 fluorescent-labelled with AF647 (Life
Technologies).
Concentrations for use of the antibodies were opti-
mized in our laboratory. Cells were analysed using
multi-colour flow cytometry (MACSQuant instrument
from Miltenyi Biotech and BD FACSCanto II instrument
from BD Biosciences). Data were analysed using FlowJo
Software (Data analysis Software, Ashland, OR).
Determination of cell death by apoptosis
Cells were labelled with Annexin-V-APC (Affimetrix
eBioscience, Vienna, Austria) [21]. Cells were analysed
using single colour flow cytometry.
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Chemokine beads assay
Levels of the human chemokines CCL2, CCL5,
CXCL8, CXCL9 and CXCL10 were quantified in su-
pernatants using a human chemokine beads assay
(Human Chemokine Kit, BD Biosciences) following
manufacturer’s recommendations. Beads were analysed
using multi-colour flow cytometry and concentrations
of chemokines were determined by comparison with
the standard material included in the kit.
Real-time RT-PCR
JEV RNA was detected by real-time RT-PCR assay. RNA
from supernatant and cells were separately extracted
using TRIzol method (Life technologies) supplemented
with glycogen (Ambion). As internal control, in vitro en-
hanced green fluorescent protein (EGFP) transcript was
added to samples in TRIzol before further steps of RNA
extraction. EGFP primers and probe were specific for
EGFP transcript sequence: forward primer 5′-GGGCA
CAAGCTGGAGTACAAC-3′, reverse primer 5′-CACC
TTGATGCCGTTCTTCTG-3′ and probe YYE-acaacag
ccacaacgtctatatcatggcc-BHQ-1 [22]. JEV primers and
probe were specific for the 3′ NTR region: forward
primer 5′-GGTGTAAGGACTAGAGGTTAGTGG-3′, re-
verse primer 5′-ATTCCCAGGTGTCAATATGCTGTT-
3′ and probe FAM-cccgtggaaacaacatcatgcggc-TAMRA
[23]. Reference dye was ROX (Life technologies). Real-
time RT-PCR program was as follow: reverse transcription
for 30 min at 50 °C; inactivation of reverse transcriptase
and activation of DNA polymerase for 5 min at 95 °C; 50
cycles of denaturation for 15 s at 95 °C and annealing for
30 s at 60 °C and elongation for 30 s at 72 °C. Real-time
PCR was performed with the SuperScript III Platinum
One-Step qRT-PCR System (Life technologies) using 7500
Real-time PCR system (Applied Biosystems).
Statistical analysis
Significant differences were determined with GraphPad
Prism 6 software (GraphPad software Inc., La Jolla, CA)
using the student t-Test (P < 0.05).
Results
JEV is not cytopathogenic to human microglia
A study using mouse microglia suggest that those cells
are a possible viral reservoir and consequently contrib-
ute substantially to JEV pathogenesis [17]. In order to
investigate the interactions between microglia in humans
and JEV, changes in the morphology of the cells were ex-
plored using bright field microscopy and flow cytometry.
Under the light microscope, Alum-treated human
microglia presented cellular processes with a uniform
cytoplasmic content whereas JEV vaccine exposure led
to an amoeboid shape and the presence of large intracel-
lular vacuoles of various sizes in human microglia
(Fig. 1a). Changes in morphology were confirmed by
flow cytometry (Fig. 1b). Importantly, no major changes
of the morphology of human microglia treated with ei-
ther the live JEV Nakayama or TC362 isolate at a multi-
plicity of infection (MOI) of 10 tissue culture infectious
dose (TCID)50/cell were observed (Fig. 1c and d). Then,
the viability of cells was measured in order to evaluate
whether JEV induced cytotoxicity to human microglia.
Flow cytometry analysis of cell surface externalization of
phosphatidylserine indicated by Annexin-V staining
was used to measure apoptotic cells in culture. JEV
vaccine had a tendency to increase the percentage of
Annexin-V+-microglia in comparison with the control
(Fig. 1e), but results were statistically not significant.
Both live Nakayama and TC362 isolates did not
change the frequency of Annexin-V+-microglia in
comparison with the mock control (Fig. 1e). Overall,
live JEV does not alter the viability of human micro-
glia in vitro.
Chemokines secretion of Japanese encephalitis virus-
treated human microglia varies between different virus
isolates
Cerebrospinal fluids of JEV-infected humans contain
CCL5 and CXCL8 proteins [24]. In the brain, mRNA
levels of CCL2, CCL3, CCL4 and CXCL10 are higher in
JEV-infected mice than in control mice [25]. In order to
determine the contribution of human microglia in in-
flammatory chemokine responses in JEV infection, levels
of CCL2, CCL5, CXCL8, CXCL9 and CXCL10 were
measured in supernatants using a chemokine beads
assay and flow cytometry. Untreated human microglia
demonstrated a constitutive production of chemokines
that did not alter upon treatment with Alum or Mock
(data not shown). In addition, treatment of cells with
JEV vaccine did not affect chemokines’ production. In
contrast, live Nakayama isolate at an MOI of 10
TCID50/cell, enhanced the production of CCL2, CXCL9
and CXCL10, but not of CCL5 and CXCL8. At a similar
MOI, live TC362 isolate exclusively increased levels of
CXCL9 (Fig. 2a). Moreover, chemokine responses of live
JEV-treated human microglia were viral dose-dependent
(Fig. 2b). However, JEV did not induce IFN-β and influ-
ence IL-1β production in human microglia cultures (data
not shown). To conclude, live JEV is able to modulate
the production of inflammatory chemokines in human
microglia in a dose-dependent.
Japanese encephalitis virus enhances CX3CR1 expression
in human microglia
In various flavivirus infections such as for dengue and
JEV, chemokine receptors have been shown to be critical
in the disease outcome [26, 27]. In order to explore the
influence of JEV on the expression of chemokine
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receptors on human microglia, modifications in the ex-
pression of chemokine receptors of the CC, CXC and
CX3C sub-families were investigated using flow cytome-
try. After 24 h of exposure to JEV vaccine, the expres-
sions of CCR1, CCR2, CCR3, CCR4, CCR5, CCR7,
CXCR1, CXCR4 and CX3CR1 were modified on both
human M-MG and BdMG in comparison with control
cells; CXCR5 was altered on BdMG but not M-MG
(Additional file 1: Figure S1). This supported the validity
of the model of in-vitro generated microglia in compari-
son to primary cells.
Expressions of CCR5 and CX3CR1 on untreated hu-
man microglia were not significantly modified by
treatment with Alum or Mock (data not shown). Signifi-
cantly, both the frequencies and levels of expression of
CCR5 and CX3CR1 on M-MG were higher upon treat-
ment with JEV vaccine. At an MOI of 10 TCID50/cell,
both Nakayama and TC362 isolates modified CX3CR1
but not CCR5 on M-MG, in terms of both frequencies
and levels of expression of the chemokine receptor
(Fig. 3a). In addition, higher doses of JEV led to higher
expression of CX3CR1 on human microglia (Fig. 3b).
While CX3CR1 expression on JEV vaccine-treated cells
was up regulated as fast as 1 h and stabilized up to 48 h,
live JEV induced transient up-regulation of CX3CR1 ex-
pression, with a peak at 24 h (Fig. 3c). Importantly, pri-
mary human microglia also demonstrated increased
frequencies of CX3CR1
+-cells upon treatment with inac-
tivated and live JEV. Interestingly, an MOI of 0.1
TCID50/cell of live JEV was necessary to modify CX3CR1
expression on BdMG (Fig. 3d). Higher MOIs did not
affect CX3CR1 expression on BdMG (data not shown).
Overall, JEV significantly enhanced CX3CR1 expression
on human microglia in a dose- and a time-dependent
manner.
Both JEV vaccine and live JEV enhance MHCII expression
on CX3CR1
+ human microglia
In the CNS, microglial cells link the innate and the
adaptive immunity by presenting MHC molecules
loaded with exogenous antigen to T-cells. Microglia cells
have a constitutive, but low expressions of MHC class I
and II that increase in response to insults [15]. Conse-
quently, the effect of JEV on the expression of MHC
class I and II on human microglia was assessed using
flow cytometry. No differences in MHCI expression
were perceived on M-MG upon treatment with JEV vac-
cine and live JEV (Fig. 4a). While MHCII expression on
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human microglia observed in (a and c). Black gate delineates microglia cells excluding other cell types and cell debris. e Histogram bars presenting the
levels of Annexin-V+-human microglia. Data are of 2 independent experiments with each condition performed in triplicate cultures. The bars represent
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M-MG was enhanced upon treatment with JEV vaccine,
no modifications were observed if treated with live JEV
isolates (Fig. 4b).
Since live JEV was inefficient to influence the expres-
sion of MHCII in the total microglia cell population, fur-
ther study focused on the impact of JEV on MHCII
expression in various subsets of human microglia co-
stained for MHCII and CX3CR1 before flow cytometry
analysis. Control M-MG had low levels of expression for
both MHCII and CX3CR1 whereas control BdMG
were negative for both CX3CR1 and MHCII. Upon
exposure to JEV vaccine, both M-MG and BdMG
were of two major microglia subsets: one was
CX3CR1
-/MHCII+ (Fig. 4c: quadrant Q3) and another
was CX3CR1
+/MHCII+ (Fig. 4c: quadrant Q4). Be-
cause M-MG showed stronger responsiveness than
BdMG to JEV exposure, further analysis were done
using M-MG. In order to identify the most suscep-
tible human microglia subset to JEV exposure, the
frequencies of the CX3CR1
+/MHCIIhigh (Fig. 4d: red
gate) and the CX3CR1
+/MHCIIlow (Fig. 4d: blue gate)
subsets were compared. In control cells, the ratio of
CX3CR1
+/MHCIIhigh over CX3CR1
+/MHCIIlow was low
with values of 0.89 (±.0.3) and 0.69 (±.0.17) upon exposure
to alum and mock antigen respectively (Fig. 4e). This de-
tailed analysis revealed that upon exposure to JEV vaccine,
in particular, but also to both Nakayama and TC362 live
isolates at an MOI of 10 TCID50/cell, the ratio of
CX3CR1
+/MHCIIhigh over CX3CR1
+/MHCIIlow signifi-
cantly increased with values of 2.57 (±.0.88),1.25 (±.0.36)
and 0.86 (±.0.26), respectively (Fig. 4e). To conclude, JEV
led to co-enhancement of CX3CR1 and MHCII on a sub-
population of human microglia.
Human microglia support JEV replication and virus
transmission to susceptible cells
Mouse microglia are productively infected by JEV [17].
Therefore, the infection of human microglia by
Nakayama isolate was evaluated using flow cytometry
and transmission electron microscopy. Over 80% of
BdMG stained for intracellular virus, whereas less than
2.5% of M-MG were positive for intracellular virus de-
tection (Fig. 5a). Importantly, intracellular vacuoles and
icosahedral JEV particles of ~50 nm diameter were
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visible in M-MG using transmission electron microscopy
(Fig. 5b).
In order to evaluate the support of human microglia
in JEV propagation, viral RNA and infectious particles
were analysed in such cultures. First, JEV replication in
human microglia was assessed by quantification of viral
RNA in cells and supernatants using real-time RT-PCR.
In order to detect de novo synthesis of JEV RNA, un-
bound virus was washed away after a 2 h step of virus
attachment on cells. Then, viral RNA was measured over
a time period of 6 days post-infection (p.i). In both M-
MG and BdMG cell extracts, the eclipse phase of virus
replication was characterized by a drop of viral RNA
during the first 24 h of infection. This was followed
by the exponential phase of virus replication to reach
a peak at 2 days p.i. Viral RNA was detected up to 6
days p.i. (Fig. 5c, upper panels). In parallel, viral RNA
was measured in supernatants to determine whether
JEV RNA was released. In supernatants, an eclipse
phase was observed during the first 24 h and 48 h in
M-MG and BdMG, respectively. Then, viral RNA in
supernatants increased and was detected at 6 days p.i,
in both M-MG and BdMG cultures (Fig. 5c, lower
panels). Interestingly, M-MG allowed higher fold
change of JEV RNA compared to time point 0 h than
BdMG (Fig. 5c).
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Since viral RNA was detected in both supernatants
and cells, the infectiousness of JEV-derived human
microglia was tested. Surprisingly, titers of infectious
JEV decreased in supernatants of both M-MG and
BdMG cultures over time and no infectious JEV was
found after 6 days of exposure (Fig. 6a). Since superna-
tants of JEV-derived human microglia were not infec-
tious, the infectiousness of cell-associated JEV was
investigated. To this end, 6 days Nakayama-infected hu-
man microglia were cultured in presence of BHK-21
cells for 2 days and infectious JEV derived from BHK-21
was measured in supernatant. On one hand, if human
microglia and BHK-21 cells were cultured in cell-cell
contact condition, de novo infectious virus reached titres
of ~105 TCID50/mL and ~10
3 TCID50/mL for M-MG/
BHK-21 and BdMG/BHK-21 cultures, respectively. On
another hand, if human microglia and BHK-21 cells
were separated using transwell insert (TW), no infec-
tious JEV was detected in supernatants of both the lower
chamber containing human microglia and the upper
chamber containing BHK-21 cells (Fig. 6b). In conclu-
sion, although human microglia do not release infectious
virus, they can transmit JEV to neighbouring cells in a
cell-cell contact manner.
Discussion
Interactions between JEV and microglial cells have been
demonstrated in various species including rats, mice and
macaques. Up to date, interactions between JEV and hu-
man microglia were shown using cell lines. Here, human
primary microglia isolated from brains of cadavers and
an in-vitro model of human blood monocytes-derived
microglia were employed. Although microglia originate
from the yolk sack during embryogenesis, monocytes
can contribute to the microglial cell population after
birth, justifying the use of this culture model [13, 14].
Furthermore, in West Nile virus (WNV)-infected mice,
CNS-infiltrating inflammatory monocytes have been
shown to be microglia precursors [28]. Our data demon-
strate that primary and in-vitro generated human micro-
glia show differences in sensitivity to JEV exposure, in
terms of E protein expression, but both human microglia
models supported viral propagation and shared the over-
all chemokine receptor pattern. Therefore, human blood
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monocyte-derived microglia represent a valid model to
study microglia-related disease pathogenesis, such as for
JE.
JE is characterized by uncontrolled inflammatory re-
sponses in the periphery and in the CNS. JEV-infected
patients present CSF-derived CCL5 and CXCL8 [24] and
chemokines such as CC2, CCL3, CCL4 and CXCL10 are
expressed in brains of JEV-infected mice [25]. In the
brain, microglia is one source of cytokines and chemo-
kines including interleukin (IL)-6, IL-1β, CCL2 and
CCL5 in various species including mice and primate
models [29–32]. Here, JEV-exposed microglia had en-
hanced production of CCL2, CXCL9 and CXCL10, indi-
cating the possible contribution of human microglia in
the presence of pro-inflammatory chemokine in the
brain compartment of JE patients. Nevertheless, chemo-
kines may have either detrimental or beneficial impact
for the outcome of the disease. For example, the inter-
action of CCL2 with CCR2 orchestrates the recruitment
of inflammatory monocytes into the brain of WNV-
infected mice in a pathogenic manner [28]. In contrast,
the signalling CXCL10/CXCR3 is implicated in the
infiltration of virus-specific CD8+ T lymphocytes into
the brain leading to a prolong survival of WNV-infected
mice [33]. In JEV-infected mice, CD8+ T lymphocytes
accumulate in the brain [27] and the activity of cytotoxic
lymphocytes partly mediates protection against JEV [34].
Indeed, impaired activity and trafficking of CD8+ T-cell
into the CNS contribute to increased mortality of
CCR5-deficient mice exposed to JEV [27]. With our data
in mind, also in human, microglia-derived CCL2, CXCL9
and CXCL10 may contribute to leukocyte trafficking
into the CNS, required for JE recovery.
Interestingly, exposure of human microglia to different
JEV isolates led to differences in the level and the signa-
ture of chemokine responses. These differences may be
explained by differential binding and entry efficiency of
the viruses to the host cell. JEV interacts with its still un-
identified host cell receptor via the viral envelope E pro-
tein [35]. Modifications of the E protein can alter JEV
binding and penetration into the target cell [36]. An-
other explanation could be related to the activation of
specific pattern recognition receptors (PRR) upon JEV
infection. Interestingly, the activation of certain PRRs
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leads to contrasting regulation of JE. Indeed, Toll-like re-
ceptor (TLR)3-/- but not TLR4-/- mice are highly suscep-
tible to JE characterized by severe CNS inflammation
[37]. In microglia, both the endosomal TLR3 and the
cytosolic retinoic acid-inducible gene 1 (RIG-I) sense the
presence of JEV. Interestingly, JEV-induced CCL2 pro-
duction has been shown to be abrogated in microglia of
RIG-I-, but not in TLR3-knockdown mice [32]. Al-
though multiple PRR are able to sense the presence of
JEV, the cellular localization of virus particles and the
activation of specific PRRs seem to be crucial to generate
an efficient and non-pathogenic inflammatory response.
A histological study of the brain in JEV-infected ma-
caques showed that activated microglia cells express MHC
class II [31]. Our results revealed a tendency of expression
of MHC class II on activated CX3CR1
+-human microglia
upon exposure to JEV. MHC class II is also increased on
JEV-exposed human MoDC, but not MDM [11, 12].
MHC class II is involved in the reactivation of virus-
specific CD4+ T-lymphocytes. Helper T-cells accumulate
in the CNS of JEV-infected mice [27] and are a critical
source of IFN-γ which promotes JEV clearance [34]. In
this context, it was interesting to note that human micro-
glia exposed to live JEV showed weak modification of
MHC class II on CX3CR1
+ microglia. This would limit
their ability to present antigen to local virus-specific CD4+
T-cells.
CX3CR1 was consistently up-regulated on JEV-
exposed human microglia. Since CX3CR1 is mainly
expressed by microglia and its unique ligand CX3CL1 is
primarily expressed by neurons [38, 39], the CX3CL1/
CX3CR1 signalling is central for microglia-neuron inter-
actions regulating neuroinflammation, neuroprotection
as well as chemotaxis. CX3CL1 inhibits the production
of pro-inflammatory cytokines by microglia [40] which
could control neurotoxicity of JEV-infected microglia-
derived inflammatory factors in mice [29]. CX3CL1
also mediates chemo-attraction of CX3CR1-expressing
microglia [38]. JEV-exposed human microglia expressed
CX3CR1 and were able to transmit JEV to susceptible
cells. Moreover, the virus transmission happened in a
cell-cell contact manner. It is thus possible to imagine
that a gradient of CX3CL1 could attract JEV-infected
CX3CR1
+-microglia allowing further JEV transmission
to neuronal cells, the major target cells of JEV.
A possible role of microglia as reservoir for JEV has
been proposed using a mouse microglia cell line [17]. In
our study, we show that human microglia supported JEV
replication without cytopathogenic effects and cell-
associated viral particles remained infectious. JEV-
infected microglia may be involved in infection of neu-
rons, contributing to JEV pathogenesis.
Conclusion
Taken together, the understanding of the role of micro-
glia in JEV pathogenesis may be helpful to identify thera-
peutic targets for JE patients. Dissecting pathogenic
from protective microglia responses might help to
understand the pathogenesis of severe virus-induced en-
cephalitis and identify possible strategies of a therapeutic
manipulation of microglia responses. In particular, the
signalling CX3CL1/CX3CR1 represents a potential target
for inflammatory diseases [41], such as for JE.
Additional file
Additional file 1: Figure S1. JEV vaccine-induced chemokine receptor
pattern in human microglia. Human M-MG and BdMG were treated with
Alum and JEV vaccine (used at a concentration of 1.2 pg/cell) at 37 °C for
24 h. Cells were stained for the indicated chemokine receptor and analysed
by flow cytometry. Representative histogram plots of (A) CC, (B) CXC and (C)
CX3C chemokine receptor expressing-human M-MG (upper panel) and
BdMG (lower panels) are shown. Cells were gated as in Fig. 1. (PDF 208 kb)
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